

Effective as of 03/04/2024

Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

<u>Information regarding Current Procedural Terminology (CPT)</u>

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Performed/Reported	Note	Interpretive Data	Reference Interval	Component Charting Name	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
0080011	CITRIC S	Citric Acid, Serum or Plasma			х		х														
2006240	SBDS FGS	Shwachman-Diamond Syndrome (SBDS) Sequencing			x																
2012039	LYSO SER	Lysozyme, Serum				х			х	х											



TEST CHANGE

Citric Acid, Serum or Plasma

0080011, CITRIC S

Specimen Requirements:

Patient Preparation:

Collect: Plain red or serum separator tube (SST).- Also acceptable:

Green (sodium heparin), lavender (EDTA), or <u>plasma</u>

preparation tube (PPTwhite (potassium EDTA).

Specimen Preparation: Transfer 2 mL serum or plasma to an ARUP <u>standard transport</u>

<u>tube</u>Standard Transport Tube. (Min: 1 mL) Test is not performed at ARUP; separate specimens must be submitted

Effective Date: March 4, 2024

when multiple tests are ordered.

Transport Temperature: Refrigerated. Also acceptable: Frozen.

Unacceptable Conditions: Room temperature specimens.

Remarks:

Stability: Ambient: 8 hours; Refrigerated: 1718 days; Frozen: 17 days

month

Methodology: Quantitative Spectrophotometry/Enzymatic Assay

Performed: Varies

Reported: 3-1211 days

Note:

CPT Codes: 82507

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:

Reference Interval:

By report



TEST CHANGE

Shwachman-Diamond Syndrome (SBDS) Sequencing 2006240, SBDS FGS

2000240, 3DD3 FG3					
Specimen Requirements:					
Patient Preparation:					
Collect:	Lavender (K2 or K3EDTA). Also acceptable: Pink (K2EDTA) or buccal swabs.				
Specimen Preparation:	Transport 5 mL whole blood (Min: 2 mL) or 2 buccal swabs (Min: 2 swabs). Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.				
Transport Temperature:	Refrigerated. Also acceptable: Room temperature. Protect fro extreme temperatures.				
Unacceptable Conditions:	<u>Prenatal specimens</u>				
Remarks:					
Stability:	Ambient: 1 week; Refrigerated: 1 week; Frozen: Unacceptable				
Methodology:	Sequencing				
Performed:	Varies				
Reported:	21-28 days				
Note:					
CPT Codes:	81479				
New York DOH Approval Status:	This test is New York DOH approved.				
Interpretive Data:					
Reference Interval:					
By report					

Effective Date: March 4, 2024



TEST CHANGE

Lysozyme, Serum 2012039, LYSO SER

2012039, LYSO SER						
Specimen Requirements:						
Patient Preparation:						
Collect:	Serum separator tube (SST).					
Specimen Preparation:	Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.4 mL)					
Transport Temperature:	Refrigerated.					
Unacceptable Conditions:	Hemolyzed, lipemic, icteric, or contaminated specimens.					
Remarks:						
Stability:	After separation from cells: Ambient: Unacceptable; Refrigerated: 5 days; Frozen: 1 month.					
Methodology:	Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)					
Performed:	Sun, Tue, Thu					
Reported:	1-5 days					
Note:	Serum lysozyme levels may be elevated in acute myelomonocytic leukemia (FAB-M4), chronic myelomonocyti leukemia (CMML), and chronic myelocytic leukemia (CML). Increased serum lysozyme activity is present in tuberculosis, sarcoidosis, megaloblastic anemias, acute bacterial infectior ulcerative colitis, regional enteritis, and Crohn disease. Elevated serum lysozyme occurs during severe renal insufficiency, renal transplant rejection, urinary tract infectio pyelonephritis, glomerulonephritis, and nephrosis.					
CPT Codes:	85549					
New York DOH Approval Status:	This test is New York DOH approved.					
Interpretive Data:						
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.						

Effective Date: March 4, 2024



A nonprofit enterprise of the University of Utah and its Department of Pathology

Effective Date: March 4, 2024

<u>Component</u>	Interpretation
Lysozyme, Serum	2.75 ug/mL or
	less
	Negative 2.76 -
	4.50 ug/mL
	Equivocal
	4.51 ug/mL or
	greater
	<u>Positive</u>

Reference Interval:

Test Number	Components	Reference Interval				
Lysozyme, Serum	Less than or equal to 4.50 ug2.75 μg/mL					

Inserted Cells

Inserted Cells